News Archives

05/13/2013

What's the best way to prevent meningitis? Are there any side effects from vaccines? These are both important questions to consider when getting vaccinated. Watch as pediatrician Dr. Greenberg answers these questions and more as he shares his insight to parenting expert Maureen Dennis. The answers might surprise you.

Voices of Meningitis is a Canadian collaborative educational initiative of Sanofi Pasteur Ltd (Canada) and Meningitis Research Foundation of Canada to educate parents about meningococcal disease.

05/06/2013

New Kirkland distribution center to accompany new head office in a total $12M investment

 

Montreal, Canada - May 6, 2013 - Global healthcare leader Sanofi inaugurated its new Canadian corporate head office this morning in Laval, Quebec, in the company of Mr. Alexandre Duplessis, Mayor of Laval, His Excellency Philippe Zeller, Ambassador of France to Canada and Mr. Nicolas Marceau, Quebec Minister of Finance and the Economy. The new offices, together with a new Canadian center for distribution in Kirkland, Quebec, form a renewed investment of $12M by Sanofi in the province.

Sanofi companies in Canada include Sanofi Canada (pharmaceuticals), Sanofi Pasteur (vaccines), Sanofi Consumer Health (health and beauty), Genzyme (rare diseases) and Merial (animal health). Together they employ more than 1,700 Canadians and, in 2012, invested $122 million in R&D in Canada, creating jobs, business and opportunity throughout the country.

“As part of Laval’s Biotech City, we remain committed to bringing innovative new medicines to Quebec and Canada, and hope to those living with diabetes, cancer and other diseases” said Jon Fairest, President and Chief Executive Officer of Sanofi Canada. “Our new head office and distribution center ensure that Sanofi continues to benefit from the expertise in the life sciences sector that Quebec has to offer.”

The new head office, which includes large open concept areas designed to encourage collaboration, innovation and cross-functional partnership between teams, will continue to house Sanofi’s Canadian Clinical Study Unit (CSU) currently overseeing close to 70 clinical trials across the country. The Kirkland distribution center brings together the company’s consumer health products and pharmaceuticals under one roof. It will also house a new cosmeceutical* laboratory for the purposes of continuing innovation in Sanofi Consumer Health’s NeoStrata® brand and bringing new health and beauty products to market.

“Sanofi has a 45-year history in Laval dating back to 1968 with the construction of the Octo Laboratories site, later becoming Nordic, and eventually the company we are today,” said Jon Fairest. “During this time, we have evolved significantly from our beginnings as a pharmaceutical company. Today, our goal is to do more than introduce products to market. We aim to serve our patients, providing them with care and expertise, while making a greater contribution to the sustainability of healthcare in Canada. Our new site is a reflection of that spirit and the culture we strive to create as healthcare company.”

 

Supporting the future of science

Underscoring Sanofi’s commitment to the future of science and its ties to the Laval community, the company invited school children from the local École Curé-Antoine-Labelle and Laval Liberty High School to meet Eunice Linh You and David Drouin, two of this year’s provincial winners of the Sanofi BioGENEius Challenge Canada – a national, biotechnology-focused science competition for high school and CEGEP students. The aspiring young scientists hosted an “Ask a GENEius” session, answering questions from the audience about their scientific aspirations and winning projects.
 

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

 

About the Sanofi BioGENEius Challenge Canada (SBCC)

Celebrating its 20 anniversary in 2013, the Sanofi BioGENEius Challenge Canada (SBCC) is a national, biotechnology-focused science competition that exposes high school and CEGEP students to career possibilities and reveals the breadth of endeavour that makes up the bio-economy.

The SBCC gives high school and CEGEP students from across Canada the chance to pour their creativity, curiosity and scientific skills into cutting-edge research projects that tackle some of the day’s toughest challenges—from cancer and Alzheimer’s disease to crops and the environment.

Students gain exposure to the exciting field of biotechnology—and the opportunities a career in the bio-economy might hold for them. The SBCC helps build Canada’s biotechnology capacity by offering the next generation of scientists the opportunity to gain hands-on experience of what it takes to succeed in the bio-economy.

*Cosmeceutical is a marketing term referring to cosmetic products that are known to health care practitioners.These products are not pharmaceuticals.

 

For further information:

Joanne Kennedy                                                         Stephanie Lyttle

Sanofi Canada                                                            NATIONAL Public Relations

TEL.: 514 956-4188                                                    TEL.: 514-843-2365 

CELL.: 514 235-4380                                                  CELL.: 514-501-8685

 

05/01/2013

Montreal, May 1, 2013 –The HEC Montréal Foundation and Sanofi Pasteur Canada announced today a five-year partnership aimed at improving business innovation and creativity.  Sanofi Pasteur will contribute $100,000 to the HEC Montréal Foundation to support programs and services at HEC Montréal, and to provide scholarships for students actively involved in Mosaic, an HEC Montréal group focused on the management of innovation and creativity. The donation was made as part of Campus Montréal, a major fundraising campaign led jointly by HEC Montréal, Polytechnique Montréal and Université de Montréal.

Ludovic Egglefield-Frenette, Aline Massouh, Alice Niyizurugero and Fabio Prado Saldanha are the recipients of the first Sanofi Pasteur scholarship of $2,500 each. The students were selected for their outstanding academic achievement and contribution to Mosaic.

“We are extremely appreciative of Sanofi Pasteur’s support for our students,” said Laurent Simon, HEC Montréal management professor, who co-founded Mosaic with Professor Patrick Cohendet in 2007. “This support reflects Sanofi Pasteur’s commitment to the next generation of managers and the importance of integrating creativity in the management process, which will be an essential skill for managers in the years and decades to come.” 

“As a leader in vaccine R&D and manufacturing, Sanofi Pasteur recognizes that innovation – in all its forms – is critical for a healthy, competitive Canadian economy,” said Mark Lievonen, President, Sanofi Pasteur Canada. “We are pleased to support HEC Montréal and the cutting-edge research being done under its Mosaic program.” 

Mosaic is a group of researchers and professors from different disciplines working on boosting innovation and creativity. The group studies, exchanges and compares creative approaches and practices from diverse fields ranging from industry and arts to science. The aim is to analyze the creative process and its management from a multi-disciplinary, intercultural, international and intergenerational perspective.

 

About HEC Montréal

HEC Montréal is a university institution with over 12,000 students enrolled in its many management programs, from the undergraduate to postgraduate level, and also trains more than 7,000 executives and managers every year. It is one of the most active Canadian business schools in research, thanks to some fifty research units, with 25 chairs including 7 Canada Research Chairs. HEC Montréal is a Francophone institution, with 270 professors, that offers a number of programs in more than one language. Since its founding in 1907, the School has trained more than 71,000 students in a wide variety of management fields.

hec.ca

 

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi Pasteur, the vaccines division of Sanofi, provides more than 1 billion doses of vaccine each year, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, Sanofi Pasteur offers the broadest range of vaccines protecting against 20 infectious diseases. The company's heritage, to create vaccines that protect life, dates back more than a century. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than EUR 1 million in research and development. For more information, please visit: www.sanofipasteur.com or www.sanofipasteur.ca

 

About Campus Montréal

When they decided to join forces to mastermind a major fundraising campaign, HEC Montréal, Polytechnique Montréal and Université de Montréal chose to adopt a shared signature. Campus Montréal represents the alliance between the three institutions that form a dynamic and modern university complex. This unique brand is used for all communications made throughout the fundraising campaign.

www.campus-montreal.ca

 

For more information :

Julie Lajoye : 438 823-1328 or julie.lajoye@hec.ca.

04/30/2013

In 2012, Sanofi Pasteur Toronto embraced Sanofi’s Environmental Sustainability goals and made a commitment to develop initiatives to significantly reduce its environmental footprint. This report highlights these efforts and results for 2012, and summarizes plans for 2013.

04/24/2013

Model, snowboarder and meningitis survivor Amy Purdy feels lucky: find out why.

 

Meningitis is a serious illness which can cause death in less than 24 hours. Active immunization is the best protection.

Since 1974, Sanofi Pasteur has been present in the fight against meningitis with the Meningo A+C vaccines, which continue to play a vital role in the prevention of meningococcal diseases in Africa and other regions.

From the 1981 launch of Menomune® onwards, patients were able to benefit from our first tetravalent polysaccharide vaccine against serogroups A, C, Y and W-135. The range was enlarged in 2005 with the introduction of Menactra® which is licensed in more than 40 countries.

Today, Menactra® is the only tetravalent conjugate vaccine indicated for children (from nine months old).

Pages